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Abstract
Background We investigated the expression of two av
integrins, avb3 and avb5, in gastric cancer (GC) by testing
the following hypotheses: that these molecules are
expressed in GC; that they are implicated in GC biology;
that they help to distinguish between the two major histo-
logical subtypes of GC, according to Laure´n; and that they
are prognostically relevant.
Methods Formalin-fixed and paraffin-embedded tissue
samples from 482 GC samples were stained immunohis-
tochemically using rabbit monoclonal antibodies directed
against avb3 (EM22703) and avb5 (EM09902). Immuno-
staining of tumor, stroma, and endothelial cells was eval-
uated separately by the quantity and intensity, generating
an immunoreactivity score. The immunoreactivity score of
both antibodies was correlated with clinicopathology data
and patient survival.
Results Each integrin was expressed in at least one tumor
component in all GCs. Both were expressed significantly
more often in the intestinal phenotype according to Laure´n.
Moreover, patients who grouped as ‘‘positive’’ for
expression of avb3 on endothelial cells, and patients with
an intestinal type GC, grouped as ‘‘negative’’ for expres-
sion of avb5 on stroma cells, had significantly longer sur-
vival. The expression of avb5 on stroma cells was
confirmed to be an independent prognostic factor of
intestinal-type GC.
Conclusion The expression of avb3 and avb5 in at least
one tumor component in all GC samples is an interesting
new result that should form a basis for further investiga-
tions; for example, regarding selective integrin antagonists
and the value of avb3 and avb5 as putative prognostic
biomarkers. Moreover, both markers might be helpful in
the routine classification of GC subtypes.
Keywords Integrins  avb3  avb5 
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Introduction
In recent decades we have witnessed major advances in the
understanding of the epidemiology, pathology, and patho-
genesis of gastric cancer (GC). Infection with Helicobacter
pylori or Epstein–Barr virus and dietary and lifestyle fac-
tors contribute to the risk of developing GC. This progress
has been accompanied by the introduction of chemotherapy
for GC, which is evolving continuously and which has
improved patients’ survival [1–3]. Evidence is
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accumulating that patient prognosis and treatment response
depend not only on the tumor stage but also on tumor-
specific alterations of both gene expression and various
signaling pathways. The two major histological subtypes of
GC according to Laure´n, diffuse-type and intestinal-type
GC, have distinct tumor dissemination patterns and show
diverse pathogeneses and expression profiles, likely
resulting from molecular differences in tumor epithelial
and stroma cells [4, 5]. Although the distinction between
diffuse and intestinal subtype in GC has prognostic sig-
nificance, it is still widely neglected in patient-tailored
treatment of GC [6, 7].
Integrins are a family of 24 heterodimeric, multifunc-
tional glycoproteins. As cell adhesion molecules and cell
surface receptors, they mediate cell-to-cell and cell to
extracellular matrix interactions, and are involved in a
great variety of physiological and pathological processes
[8]. They are composed of an a subunit, and a b subunit
that connect to the cytoskeleton and interact with multiple
signaling pathways; the a–b combination determines inte-
grin ligand binding specificity and intracellular signaling
[9]. Integrins are important regulators of differentiation,
tumor growth, survival, migration, and invasion. In
malignant tumors, they are involved in several processes
that characterize the tumor phenotype [10]. Several inte-
grin heterodimers have already been shown to be involved
in GC biology and to have a significant value as prognostic
markers. An increased expression of integrin avb6 is linked
significantly with reduced survival, lymph node metastasis,
and the number of cancer-associated fibroblasts, and inte-
grin a5b1 is described to be significantly associated with
tumor differentiation, TNM stage, and recurrence [11–15].
Recently, integrins, particularly avb3 and avb5, have been
recognized as putative targets for the treatment of several
cancers, which has spurred research on integrins in cancer
biology [16–19]. Thus, the characterization of integrin
distribution in human tumors is of great interest. At present
little is known about the expression of integrins avb3 and
avb5 in GC, mainly owing to the lack of antibodies suitable
for use on formalin-fixed and paraffin-embedded (FFPE)
tissue [20]. Only two studies to date have focused on
integrins avb3 and avb5 in GC. Those studies differ sig-
nificantly from our study, as they investigated only 19 and
55 cases, respectively, and relied on frozen tissue sections.
Also, owing to the small number of cases, they were unable
to correlate the expression pattern of avb3 and avb5 in GC
with clinicopathological patient characteristics [12, 21].
Recently, comprehensive molecular characterization
including whole-genome sequencing was performed in GC
and nontumor pairs for integrative genomic analysis of GC
[22, 23]: 20 of 26 genes of the integrin subunits were
deregulated in GC pathways, involving also cell adherens
junctions, angiogenesis, and focal adhesion. Thus,
deregulation of integrin expression may be a tumor-bio-
logical hallmark of GC or its specific subtypes. However,
data on integrin expression on a protein level in GC are still
sparse, and validation of genomic data is urgently needed.
Here we investigated the expression of avb3 and avb5 in
GC on the protein level, examining the following
questions:
1. Are integrins expressed in GC?
2. Are integrins implicated in GC biology?
3. Do integrins discriminate the GC subtypes?
4. Is the expression of integrins prognostically relevant?
Materials and methods
Study population
From the archive of the Institute of Pathology, University
Hospital Kiel, we identified 611 Caucasian patients who
underwent either total or partial gastrectomy for adeno-
carcinoma of the stomach or esophagogastric junction
between 1997 and 2009. The following patient character-
istics were retrieved: type of surgery, age at diagnosis,
gender, tumor size, tumor localization, tumor type, tumor
grade, depth of invasion, number of lymph nodes resected,
and number of lymph nodes with metastases. Each resected
specimen underwent gross sectioning and histological
examination by surgical pathologists. The date of patient
death was obtained from the Epidemiological Cancer
Registry of the state of Schleswig–Holstein, Germany.
Follow-up data for those patients who were still alive were
retrieved from hospital records and general practitioners.
Ethical approval was obtained from the local ethical review
board (D 453/10). All patient data were pseudonymized
prior to inclusion in the study. Tissue was included if (1) an
adenocarcinoma of the stomach or esophagogastric junc-
tion was confirmed histologically, (2) the date of death or
survival data were available, and (3) the overall tumor
mass was large enough to get three tissue microarray
(TMA) punches. Exclusion criteria were defined as fol-
lows: (1) histological examination identified a tumor type
other than adenocarcinoma; (2) patients had undergone
perioperative chemotherapy or radiotherapy; and (3) the
date of the patient’s death or survival data had not been
recorded.
In total, 482 patients fulfilled all study inclusion criteria.
The clinicopathological patient characteristics are sum-
marized in Table 1. In accordance with Laure´n, an intes-
tinal type was found in 247 patients (51.2 %), a diffuse
type was found in 152 patients (31.5 %), a mixed type was
found in 30 patients (6.2 %), and an unclassifiable type was
found in 53 patients (11.0 %).
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Histology
Tissue specimens were fixed in formalin and embedded in
paraffin. Deparaffinized sections were stained with hema-
toxylin and eosin. Histological reexamination of primary
tissue sections was done for all cases to ensure if inclusion
criteria were confirmed. Tumors were classified according
to the Laure´n classification [4] and were reexamined by
two surgical pathologists. The pTNM stage of all study
patients was determined according to the seventh edition of
the Union for International Cancer Control (UICC)
guidelines [24] and the recent proposal (Kiel stage) of
Warneke et al. [25].
Tissue microarray construction
FFPE tissue samples were used to generate TMAs as
described previously [26]. Briefly, three morphologically
representative regions of the paraffin ‘‘donor’’ blocks
(tumor) were chosen, and tissue cylinders of 1.5-mm
diameter were punched from these areas. Afterwards, the
tissue cylinders were inserted into a new ‘‘recipient’’ par-
affin block using a custom-built instrument (Beecher
Table 1 Clinico-pathological patient characteristics
Patients (n) 482
Age (years)
























pN3 (a/b) 189 (39.5)
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786 C. Bo¨ger et al.
123
Instruments, Silver Spring, MD, USA). The new recipient
paraffin blocks were warmed in a 60 C heating cabinet for
7 min to create a sufficient bond between the tumor tissue
and the recipient block paraffin. Then, 2.5-lm-thick serial
sections were obtained from the new recipient paraffin
blocks, dried in a 60 C heating cabinet for 6 h, and stored
in polystyrene slide storage boxes at 8 C until use.
Immunohistochemistry
For immunohistochemistry we used two monoclonal rabbit
antibodies, directed against avb3 (EM22703) and avb5
(EM09902). The biochemical specificity of the antibodies
against integrins, which were used in this study, was pre-
cisely defined previously [20]. All immunoreactions for
validation used the Ventana BenchMark XT automated
slide staining system using the reaction buffer ULTRA
LCS, EZ Prep (75 C; 4 min), protease 2 (12 min), UV
inhibitor, ultraView Universal DAB, hematoxylin II, and
bluing reagent (all reagents from Roche Diagnostics,
Mannheim, Germany). Antibodies were diluted in antibody
diluent (Zytomed Systems, Berlin, Germany) and were
applied at 10 lg/ml for 36 min at 36 C (anti-avb3), or
0.1 lg/ml for 40 min at 40 C (anti-avb5). To determine
the optimal antibody dilution, kidney sections were stained
with serial dilutions of the primary antibodies (1 ng to
100 lg/ml). Distinctive staining patterns of avb3 (mainly
glomerular) and avb5 (glomerular and descending tubuli)
were used as reference positive controls for calibration and
initial titration of the antibodies. Rabbit IgG preimmune
sera (Abcam, Cambridge, UK) served as negative controls.
Negative and positive controls were applied in parallel for
each staining series. Additionally, we conducted immuno-
histochemistry with a monoclonal antibody directed
against E-cadherin as previously described [6]. The
E-cadherin staining results were correlated with those of
avb3 and avb5.
Study design
TMA sections from each tumor were stained with anti-
bodies directed against avb3 and avb5. The staining results
were correlated with clinicopathology and survival data.
Evaluation of immunostaining
The quantity, intensity, and localization of immunoreac-
tivity of both antibodies were evaluated by applying an
immunoreactivity scoring system. Immunoreactivity was
evaluated separately for tumor cells, stroma cells, and
endothelial cells. Stroma cells included all cells of the
tumor stroma (e.g. fibroblasts), and excluded endothelial
cells, which were evaluated separately.
The previously described immunoreactivity scoring
system [27] consisted of two components. Category A
rated the percentage of immunoreactive cells and was
graded as 0 (negative), 1 (up to 10 % positive cells), 2
(10–50 % positive cells), 3 (51–80 % positive cells), and 4
(81–100 % positive cells). Category B documented the
intensity of immunostaining as 0 (no immunostaining), 1
(weak), 2 (moderate), or 3 (strong). The addition of cate-
gory A and category B resulted in an immunoreactivity
score (IRS), with was separately applied for tumor cells
and stroma cells. The IRS ranged from 0 to 7 for tumor
cells and from 0 to 7 for stroma cells. The intensity of the
endothelial immunoreaction was rated as 0 (negative), 1
(weak), 2 (moderate), or 3 (strong).
Statistical analysis
Statistical analyses were done using SPSS 20.0 (IBM, New
York, NY, USA). For comparison purposes, the IRS for
tumor cells, the IRS for stroma cells, and the endothelial
immunoreaction were partitioned at the median, and
patients below the median were classified as ‘‘negative.’’
Median overall survival was determined using the Kaplan–
Meier method, and the log-rank test was used to determine
significance. To investigate the prognostic relevance, we
included all variables having p\ 0.100 in multivariate
analysis using a Cox regression model and the backward
logistic regression method (pin and pout = 0.05) to reduce
the model to the independent variables. The significance of
correlation between clinicopathological parameters and
each antigen’s IRS was tested using Fisher’s exact test. For
parameters of ordinal scale (T category, N category, tumor
stage), we applied Kendall’s tau test instead. To account
for the effects of multiple testing, we applied the explor-
ative Simes (Benjamini–Hochberg) procedure [28]. We




Both avb3 and avb5 were expressed in at least one tumor
component in all GC samples investigated (Fig. 1).
Expression in tumor cells was mainly membranous. In
cases with a strong membranous and/or stromal expression,
an additional light cytoplasmic staining was observed.
Integrin avb3
Integrin avb3 was expressed in 119 of 457 cases (26.0 %)
in tumor cells. The percentage of stained tumor cells
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ranged from grade 0 to grade 4 (median grade 0), the
staining intensity ranged from 0 (no immunostaining) to 3
(strong immunoreaction; median 0), and the tumor cell IRS
ranged from 0 to 7 (median 0). Dichotomized by the
median, 119 cases (26.0 %) were classified as positive and
338 cases (74.0 %) were classified as negative. In stroma
cells, avb3 was expressed in 420 of 457 cases (91.9 %).
The percentage of stained stroma cells ranged from grade 0
to grade 4 (median grade 1), the staining intensity ranged
from 0 to 3 (median 1), and the stroma cell IRS ranged
from 0 to 7 (median 3). Dichotomized by the median, 247
cases (54.0 %) were classified as positive and 210 cases
(46.0 %) were classified as negative. Integrin avb3 was
expressed in endothelial cells in all cases (456 of 456;
100 %). Staining intensity ranged from 1 to 3 (median 2).
Dichotomized by the median, 363 cases (79.6 %) were
classified as positive and 93 cases (20.4 %) were classified
as negative.
Integrin avb5
Integrin avb5 was expressed in 299 of 453 cases (66.0 %)
in tumor cells. The percentage of stained tumor cells ran-
ged from grade 0 to grade 4 (median grade 2), the staining
intensity ranged from 0 to 3 (median 1), and the tumor cell
IRS ranged from 0 to 6 (median 3). Dichotomized by the
median, 246 cases (54.3 %) were classified as positive and
207 cases (45.7 %) were classified as negative. In stroma
cells, avb5 was expressed in all cases (454 of 454; 100 %).
The percentage of stained stroma cells ranged from grade 1
to grade 4 (median grade 2), the staining intensity ranged
from 1 to 4 (median 2), and the stroma cell IRS ranged
from 2 to 7 (median 4). Dichotomized by the median, 189
cases (41.6 %) were classified as positive and 265 cases
(58.4 %) were classified as negative. The expression of
avb5 in endothelial cells could not be analyzed in 125 of
482 cases owing to a strong stromal immunoreaction. In the
remaining 357 cases, avb5 was expressed in endothelial
cells in 274 cases (76.8 %). Staining intensity ranged from
0 to 2 (median 1). Dichotomized by the median, 274 cases
(76.8 %) were classified as positive and 83 cases (23.2 %)
were classified as negative.
Clinicopathological correlation
Next we studied the correlation between the expression of
the integrins and the clinicopathological patient charac-
teristics. For this purpose, we split the IRS of each marker
Fig. 1 Expression of avb3 and avb5 in gastric carcinoma. This figure
illustrates gastric carcinomas of the intestinal type according to
Laure´n with a strong membranous expression of avb3 on tumor cells
(a) and on endothelial cells (b), a moderate membranous expression
of avb5 on tumor cells (c), and a strong avb5 expression on stroma
cells (d). Original magnification 9200
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at the median into negative (at or below the median IRS)
and positive (above the median IRS) cases. Significant
correlations were found for gender, tumor type, tumor
localization, T category, tumor stage according to the
UICC and Kiel classifications, and tumor grade. Most
interestingly, diffuse-type GC exhibited a significantly
reduced expression of both integrins in tumor cells and in
stroma cells compared with intestinal-type GC. There was
no significant correlation between N category, venous
invasion, or lymph vessel invasion and the expression of
either tested marker. Co
mplete data are given in Table 2.
Subgroup analyses of intestinal-type and diffuse-type
GC showed that the endothelial expression of avb3 in
intestinal-type GC correlated significantly with the tumor
grading: avb3 was more often expressed in G1/G2 tumors
than in G3/G4 tumors. Moreover, the stromal expression of
avb5 in intestinal-type GC correlated significantly with
gender, the T category, and the tumor stage according to
the Kiel classification. By contrast, there was no significant
correlation between the expression of either marker and the
clinicopathological patient characteristics in diffuse-type
GC. Complete data are shown in Online Resource 1 and
Online Resource 2.
The expression of E-cadherin in tumor cells correlated
significantly with the expression of avb3 in tumor cells
(p\ 0.001) and stroma cells (p = 0.006) as well as with
the expression of avb5 in tumor cells (p = 0.017). There
was no significant correlation between the expression of
E-cadherin and the expression of avb3 in endothelial cells
(p = 0.141) or the expression of avb5 in stroma cells
(p = 1.000) or endothelial cells (p = 0.885). Complete
data on E-cadherin evaluation and the staining results are
given in Online Resource 3.
Prognostic significance
Patient prognosis of the entire cohort significantly depen-
ded on patient age, Laure´n phenotype, T category, N cat-
egory, lymphatic invasion, venous invasion, tumor grade,
and UICC stage and Kiel stage (data not shown). Patients
who were grouped as ‘‘positive’’ for expression of avb3 on
endothelial cells had significantly longer survival com-
pared with patients with a ‘‘negative’’ avb3 expression in
endothelial cells (Table 2, Fig. 2).
The subgroup analyses of intestinal-type and diffuse-
type GC showed that this also applied to patients with an
intestinal-type GC: these patients had significantly longer
survival if they were ‘‘positive’’ for expression of avb3 on
endothelial cells, compared with patients with a ‘‘negative’’
avb3 expression. Patients with an intestinal-type GC
grouped as ‘‘positive’’ for expression of avb5 on stroma
cells had significantly shorter survival than patients
grouped as ‘‘negative’’ (Online Resource 1).
There were no other significant correlations between
survival data and the expression of both markers.
Explorative multivariate analysis
Explorative multivariate survival analysis was done with
all parameters which had p\ 0.100 in univariate survival
analysis. For the entire study population and the diffuse-
type subgroup, T category and N category were found to
be highly significantly independent prognosticators of
patient survival. The subgroup analysis of intestinal-type
GC confirmed the independent prognostic significance of
T category, N category, lymphatic invasion, and avb5
expression on stroma cells (Table 3).
Discussion
GC is a heterogeneous disease, which still leads cancer
deaths worldwide [29]. During recent years, evidence has
accumulated indicating that patient prognosis and treat-
ment response depend not only on tumor stage, but also on
the expression and tumor-specific alteration of intracellular
signaling pathways. Different treatment strategies are
needed to specifically target the aberrant cancer signaling
pathways in GC [30, 31].
Integrins avb3 and avb5 are at the focus of several on-
cologic investigations [32–39]. Integrins drive diverse
intracellular signaling cascades, and so are involved in a
great variety of physiological and pathological processes.
They influence tumor cell proliferation, tumor cell move-
ment, and cell survival in vivo and in vitro, and their
involvement in multiple signaling pathways is crucial for
tumor progression. This all suggests that integrins may be
targets for the treatment of cancer, and this has spurred
integrin research in cancer biology [9, 40, 41]. Some
concepts for pharmacological treatment based on the
inhibition of integrins already exist [18, 19], but imple-
mentation of a therapeutic strategy demands a robust ver-
ification of integrin expression in different tumors.
Here, for the first time we have investigated the
expression of avb3 and avb5 in a large cohort of GC
patients. Our primary observations are that:
1. Integrins avb3 and avb5 were expressed in at least one
tumor component of all GC samples, which in general
suggests that GC might be an interesting target for
further studies on integrin-antagonistic cancer therapy.
2. A positive avb3 status and a positive avb5 status was
observed significantly more often in intestinal-type GC
than in diffuse-type GC. Intestinal-type GC is known


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Integrins avb3 and avb5 in gastric cancer 791
123
to have a better outcome than diffuse-type GC [6]. We
observed that a positive avb3 status showed statisti-
cally significant correlations with several clinicopath-
ological patient characteristics that are known to be
associated with a better outcome, such as a minor pT
category, a minor UICC/Kiel stage, and a better tumor
grading (G1/G2). Indeed, a positive avb5 status
accompanies at least some of these characteristics. If
we look more closely at these p values (p B 0.05), it
becomes clear that the distribution of the different
subgroups is not as divergent as the statistics indicate.
The subgroup analyses of intestinal-type and diffuse-
type GC showed that only the endothelial expression of
avb3 correlated significantly with the tumor grading,
and that only the stromal expression of avb5 correlated
significantly with the gender, the T category, and the
tumor stage according to the Kiel classification. This
indicates that the observed correlation between a
positive avb3 status and a positive avb5 status and
clinicopathological parameters that are associated with
a better outcome is mainly caused by the increased
expression of avb3 and avb5 in intestinal-type GC
compared with diffuse-type GC. On the basis of these
observations, one may speculate that both markers may
be suitable to aid histological classification of GC.
3. Patients with an increased expression of avb3 in
endothelial cells, and patients with an intestinal-type
GC ‘‘negative’’ for avb5 had significantly longer
survival. Moreover, avb5 expression on stroma cells
of intestinal-type GC was confirmed to be an indepen-
dent prognostic factor. This interesting result is
notable, as it seems that at least avb5 has potential
value as a prognostic biomarker for GC. Nevertheless,
the significance and the clinicopathological relevance
of these findings remain unclear and need to be
addressed in further investigations.
Another interesting finding was the predominant
expression of avb3 and avb5 in stromal and endothelial
cells. There is evidence that intratumoral stroma is a
Fig. 2 Kaplan–Meier curves for intestinal-type versus diffuse-type
gastric carcinoma according to Laure´n (a), avb3 expression on
endothelial cells in the entire cohort (b), avb3 expression on
endothelial cells in intestinal-type gastric carcinoma (c), and avb5
expression on stroma cells in intestinal-type gastric carcinoma (d)
792 C. Bo¨ger et al.
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predictor of survival in patients with GC [42]. Moreover,
the proven correlation between the expression of both
markers with E-cadherin confirms the well-known
involvement of integrins in cell adhesion signaling [43,
44].
In other tumor entities, a high expression level of other
av integrins has been described to be associated with tumor
progression and worse survival, which is partly contradic-
tory to our results. Previous studies mainly compared the
expression level in neoplastic versus nonneoplastic tissue.
In endometrial cancer, cervical squamous cell carcinoma,
and serous epithelial ovarian carcinoma, an upregulation of
integrin avb6 was described in tumor tissue compared with
normal cycling endometrium or nonneoplastic epithelia
[45–47]. In colorectal cancer, the overexpression of av
correlated significantly with poor prognosis [48]. In our
study, we did not compare expression levels in nonneo-
plastic versus neoplastic tissue, but focused on the differ-
ential expression of avb3 and avb5 in the diverse cellular
components of the neoplastic tissue compartment. More-
over, we used two other antibodies, with potentially dif-
ferent reactivity profiles in GC, than those that were used
previously.
However, our study shows that the tumor-biological
significance of integrins is not restricted to their expression
by tumor cells. It extends into the intratumoral stroma and
tumor vessels, and furthermore, may also depend by as yet
unknown mechanisms on the histological phenotype. The
differential expression of integrins in the tumor stroma of
different GC tumor types somewhat supports the general
observation that the tumor stroma is highly variable; for
example, with or without pronounced desmoplasia. This is
a particular hallmark of diffuse-type GC. We hypothesize
that the diffuse type, with its poorly cohesive growth pat-
tern, might be the result of decreased integrin expression of
both tumor and stroma cells. Further studies of this topic
may be productive.
One methodical issue in our study was that the pre-
treatment procedure for both antibodies was relatively
intense. Both antibodies have previously been shown to
deliver concordant staining results in frozen sections and
FFPE tissue. Regarding FFPE tissue, even small deviations
of the pretreatment temperature led to a decreased staining
intensity and quality during manual staining of anti-avb3
and anti-avb5 [49]. Such hazards can be minimized by
using fully automated staining systems, as done in the
present study, and as designed for these antibodies [20].
Nevertheless, possible incomplete antigen retrieval or
partial destruction of epitopes during the rather aggressive
pretreatment has to be generally considered.
In conclusion, this study is the first extensive longitu-
dinal investigation of the expression of integrins avb3 and
avb5 in GC. Our data support recent whole genome
sequencing data and suggest that GC is an interesting
indication for further investigations of selective integrin
antagonists, and that both avb3 and avb5 are selectively
Table 3 Explorative
multivariate survival analysis
A Cox regression was
performed with all parameters
as input which had p\ 0.100 in
univariate survival
analysis.Tumor stage (Union for
International Cancer Control
stage and Kiel stage) was
excluded from the model
HR hazard ratio
a The 95% confidence interval
is given in parentheses.
Subgroup Input parameters Independent parameters
kept in model
p value HR (95 % CI)
All cases Laure´n phenotype
T-category T-category \0.001 1.031 (1.016–1.046)








T-category T-category 0.026 1.024 (1.003–1.045)
N-category N-category \0.001 1.029 (1.014–1.044)




avb5 expression on stroma
cells





T-category T-category \0.001 1.067 (1.035–1.100)
N-category N-category 0.001 1.032 (1.014–1.051)
Lymphatic invasion
Venous invasion
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expressed in different GC classes, and might be valuable in
classification of GC subtypes. Furthermore, it is clear that
in GC at least avb5 has potential value as a prognostic
biomarker, and that both avb3 and avb5 might even be
considered as novel therapeutic targets. Further investiga-
tions are needed, which, also in consideration of the
comparison of integrin expression in tumor and nontumor
tissue, might lead to additional information regarding the
potential value of integrins avb3 and avb5 as diagnostic and
prognostic biomarkers.
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